The choice between IUI, IVF and ICSI is clinical. Donor sperm can be used in different pathways depending on age, ovarian reserve, tubal status and earlier fertility care. Before paying for matching, ask whether insemination is a reasonable option or whether IVF is medically more appropriate. Legal eligibility must also be checked.

Donor programmes require documented safeguards, which can include infectious-disease screening, identity controls and appropriate handling of samples. Ask whether test validity, storage and traceability standards are documented. The recipient and, where relevant, their partner may also need investigations. Screening reduces but does not eliminate all risks.

Carrier screening may identify a recessive genetic risk that needs to be considered alongside the egg source’s genetic findings. A “normal” genetic report never excludes every possible disease. Ask what panel was used, whether it fits the clinical circumstances and whether a genetics professional should interpret uncertain or overlapping findings.

Send fertility assessments, earlier IUI or IVF reports, relevant surgical records and any test results through an approved channel. Confirm whether samples, documents and consents can be arranged before arrival. A preliminary eligibility review is helpful, but a treatment start date should be confirmed only after the clinical and legal assessments are complete.

The first consultation should connect the stated concern to a concrete decision. The medical team can review earlier procedures, medication, medical and family history, reproductive investigations and any previous pregnancies. Ask which findings are reassuring, which need clarification and which may change the recommended approach. Rather than repeating every test from a checklist, prioritise investigations whose results could affect safety, treatment selection or timing.

It is appropriate to ask how uncertainty is handled. A result may guide a clinical choice without predicting a personal live birth. For example, an apparently normal scan cannot explain every failed embryo transfer, and a reassuring screening panel cannot exclude every genetic condition. If additional testing is suggested, request its purpose, expected interpretation and a discussion of available alternatives.

Decision point: 1

If you already have detailed treatment records, your first priority is understanding which parts remain valid. An organised record can avoid unnecessary duplication; the physician decides whether further tests are needed.

Decision point: 2

If earlier treatment did not work, bring laboratory and transfer documents rather than relying on a one-line summary. The question is not simply which test is missing, but what your previous pathway reveals.

Decision point: 3

If you will travel from another country, discuss local monitoring, clinic appointments, required consent and the ability to change travel dates. Medical timing should take precedence over flight availability.

Prepare a one-page timeline listing age, relevant medical conditions, medicines, operations, previous pregnancies and fertility procedures. Put dated reports in a clear order: hormone results; ultrasound and uterine imaging; semen analysis; laboratory records; embryo development and transfer reports; genetic findings where available. A count such as “three failed cycles” gives much less clinical detail than the actual stimulation, fertilisation, embryo and transfer records.

If you previously received a particular treatment or medication, include the dose, route, duration and clinical reason when these are known. Avoid sending unlabelled screenshots without a date or laboratory range. Ask the clinical team which documents can be reused and which may need updating. Medical information should be sent only through the secure channels approved by the clinic, with an explanation of confidentiality and consent.

A successful treatment plan connects medical evaluation, laboratory capability, logistical coordination and follow-up. Before treatment, confirm who authorises medication changes, which examinations can be completed locally, how laboratory reports will be shared and what happens if a cycle must be postponed. A comprehensive written plan also explains which decisions can only be made after new results become available.

Try to separate the decision to investigate from the decision to purchase treatment. A remote file review can identify potentially suitable options, but it does not replace examination, formal consent or verification of the local legal requirements. If your circumstances are complicated, requesting a second opinion or counselling before committing is a reasonable part of informed decision-making.

Before buying flights or choosing a treatment date, begin with a structured review of the medical history and any earlier fertility treatments. The most useful first appointment is not a sales call: it identifies the question that needs a clinical answer, reviews what is already known and explains what cannot be decided without examination. A coordinator can help organise the documents, but the medical recommendation must come from the responsible clinician.

The next stage is an individual investigation and timing plan. Some blood tests, imaging or monitoring may be performed locally if their methods and dates are acceptable to the treating team. Results must reach the clinic in readable form, with units, reference ranges and dates. Once the doctor confirms the necessary steps, the team can discuss appointments in Cyprus, possible changes to timing and appropriate follow-up after returning home.

Assisted reproductive care requires more than choosing an attractive option online. Screening, informed consent, clinical suitability and the applicable rules for donor treatment, identity, traceability, storage and family relationships can differ between jurisdictions. A procedure described on an international website may not be legally or clinically available for every applicant. Confirm the position that applies to your treatment and your country of residence before making a financial commitment.

Risks need to be explained in plain language, including uncertainty. A normal screening result cannot exclude every health or genetic risk; embryo transfer does not guarantee a pregnancy, and a positive pregnancy test does not guarantee a live birth. Pregnancy-related risks may remain relevant even when donor gametes are used. No optional investigation or add-on should be presented as universally necessary without a clinical reason and a discussion of evidence.

A useful written quote separates preliminary testing, medication, donor assessment when relevant, laboratory fertilisation, culture, transfer, freezing, storage and any clinically indicated additional procedures. Ask which items are included, optional, excluded or charged if the plan changes. If treatment involves travel, add transport, accommodation, local investigations and time away from work. Comparing only the advertised initial price may obscure major differences in the scope of care.

Discuss cancellation rules, what happens when a cycle is postponed for medical reasons, and whether any unused services are refundable. Ask about the costs of additional monitoring, subsequent transfers or embryo storage if relevant. This is also the right time to clarify what will happen after you travel home, who reads results and whether a local healthcare professional should be involved. Financial clarity is part of informed consent.

Agree in advance who will review results, how quickly urgent concerns should be reported and what clinical care is available locally. When medication or embryo transfer is involved, do not stop or change prescribed medicines based on a forum or an internet timetable. The treating team should give an individual written plan for the next contact, testing and any necessary monitoring.

If treatment does not proceed, the consultation should still end with a usable summary: what was found, which questions remain unanswered and whether another assessment or a different option is reasonable. An unsuccessful cycle also deserves a clear review rather than automatic repetition of every previous step. The patient should have access to the relevant reports and know whom to contact for clarification.